Alain Mina retweeted
Congratulations @Dr_AmerZeidan, 2026 King Hussein Cancer Research Award recipient for Lifetime Achievement – International Track from @KHCFKHCC. The awards aim to encourage Arab researchers and scientists from around the world to elevate #cancerresearch and advance the fight against #cancer and overcome it through cutting-edge scientific approaches.
jordantimes.com/news/local/d…
@SmilowCancer @YaleHematology @YNHH
Alain Mina retweeted
ألف مبروك د.عامر. تستحقّ كل التقدير.
Extremely humbled & proud to receive the 2026 King Hussein Cancer Research Life Achievement Award (international track) @KHCFKHCC by HRH Prince Talal & Princess @GhidaTalal. It is extra special since it is the 25th anniversary for KHCC where I worked in 2003 @Kinghusseincancer
Alain Mina retweeted
Replying to @YaleCancer
@YaleCancer has a robust CAR-Tcell therapy for multiple myeloma. Dr. Noffar Bar explains just how it works to treat patients. Advancements are amazing. @YaleHemOnc
wtnh.com/news/health/how-eff…
Alain Mina retweeted
A true honor to receive the @TheIACH award named after Dr Khoury who exemplified dedication to patients, mentorship; clinical research excellence, and global education on blood cancers especially myeloid malignancies. May his legacy live for eternity.
✨ We are delighted to congratulate Prof. @Dr_AmerZeidan on receiving the prestigious H.J. Khoury Excellence in Research Award at the IACH Annual Meeting 2026 in Paris.
This award recognizes outstanding contributions to hematology research and the advancement of scientific knowledge.
Congratulations, Prof. Zeidan, on this well-deserved recognition!
@Mohty_EBMT @BipinSavani
#IACH2026 #Hematology
Alain Mina retweeted
One of the many advances evolving at @YaleCancer Center involves CART-T immunotherapy for treating blood cancers. What about the future for conditions such as lupus, MS and scleroderma? Read this: yalemedicine.org/news/car-t-…
What role does allo-SCT play in MDS?
Should we transplant TP53-mutated patients?
Which patients should be transplanted in the PTCy era?
Does non-transplant cellular therapy have a future?
Leading experts addressed these questions yesterday at #iwMDSMPN26.🩸
ft. @TalhaBadarMD, @AmyDeZern, @myeloidmalig, @dralainmina, Mohamed Kharfan-Dabaja
#MDSsm #BMTsm #HemOnc
Alain Mina retweeted
.@NataliaNeparid1 sat with @WTNH Medical Mondays for a discussion on #myeloma for #BloodCancerAwarenessMonth. She explained how myeloma affects the body, as well as treatments currently available-including the recent FDA-approved pill developed at @YaleCancer that has seen great success in patients, and current clinical trials.
➡️youtube.com/watch?v=u9Jcj9lO…
@YaleHematology
Alain Mina retweeted
It's #BloodCancerAwarenessMonth and Dr. Alain Mina talks with @WTNH about treatment advances and how quality of life has really improved for patients with #leukemia in the last five years.
wtnh.com/news/health/how-leu…
@YaleCancer @YaleHematology @dralainmina @Dr_AmerZeidan
Alain Mina retweeted
How some developments at @YaleCancer have dramatically changed leukemia treatments. Details: @WTNH @dralainmina wtnh.com/news/health/how-leu…
Excited to see this in print! Congratulations @StimulatedRaman for spearheading this study showing the power of multimodal nanoscopy in revealing the hidden biology of our lymphomas in transformation. #hemepath #lymsm
In collaboration with Professors Rong Fan, Mina Xu, and Zongming Ma, we have jointly developed a novel technology, "redcat". Applied to rare Richter's transformation lymphoma samples:@RongFan8 @MinaXu7 @ZongmingMa
Alain Mina retweeted
Grateful to have hosted Dr @dralainmina @YaleCancer at @orlandohealth Cancer Institute for an outstanding Grand Rounds on redefining cure in AML across the transplant continuum.
Thank you, Alain, for sharing your expertise and spending time with our OHCI team!#Leukemia
🤖 Made with AI
Alain Mina retweeted
In this episode of The Oncology Insights Podcast, I talk about how molecular testing, cytogenetics, targeted therapy, and measurable residual disease are changing treatment decisions in acute myeloid leukemia: linkedin.com/posts/oncology-…
Alain Mina retweeted
Our newest paper @YaleCancer @Yale @YaleHematology led by Dr Alain Mina where we analyzed 12,154 #AMLsm patients who were older than 75 yr in age or unfit for intensive chemotherapy to identify factors influencing the receipt of #AMLsm-directed therapy. tandfonline.com/doi/full/10.…
Alain Mina retweeted
Fantastic Medical Crossfire Meeting on Hematologic Malignancies @gotoPER #MXH26 in NYC July 2026, with great participation from our @Yale University @YaleCancer @YaleHematology group with 7 faculty & fellow participants. Mark your calendars for July 17-18, 2027 edition
Alain Mina retweeted
Proud of our collaborative work between @ic_MDS with @HumanitasMilano which was just published in @Hemasphere_EHA. #MDSsm are biologically diverse cancers and need personalized treatment approaches. The IWG_PM introduced the MDS taxonomy, that categorizes patients into 16 genetic subgroups.
Alain Mina retweeted
Tomorrow starting at 11am CEST/5am EST at @EHA_Hematology EHA Congress, @Dr_AmerZeidan and Dr. Nikolai Podolsev will present study results during the 'Novel Treatments in #AML' session at #EHA26.
pag.virtual-meeting.org/EHA/…
@SmilowCancer @YaleHematology
Alain Mina retweeted
One of the greats! So proud to have Nikolai as our APD 🥇🍾
Congratulations to Nikolai Podoltsev, MD, PhD, @YaleHematology who was presented with The Fred S. Kantor Teacher of the Year Award by the residents of the @YaleMed @TradIMYale program.
@SmilowCancer @MarkDSiegel1 @Dr_AmerZeidan
Alain Mina retweeted
We had an outstanding brainstorming/strategic planning meeting fin the leukemia program within @YaleCancer @YaleHematology including clinical, translational, registry-based & HOER projects in #AMLsm #MDSsm #MPNsm & involving many residents, fellows, trainees & other team members
Alain Mina retweeted
We had a nice event to celebrate three of our malignant hematology colleagues who will be leaving Yale: our amazing transplant APP Alfredo Axtmayer to join industry, our postdoc Luca Lanino who will be joining DFCI for a leukemia fellowship, and our graduating heme/onc fellow Ted Getz who will be joining leukemia faculty at NYU. We also welcomed our two graduating fellows who will be joining our malignant heme faculty in the lymphoma program Etienne Leveille and Cristian Taborda.








































